A pharmaceutical company does not usually announce a bond. It announces a rights offering, a bonus issue, a stock split, sometimes a fresh equity placement. Techno Drugs Ltd. did something different on Sunday. The Board of Directors, meeting for the 196th time, decided to convene an Extraordinary General Meeting to approve the issuance of a Tk 50 crore bond. The market noticed within hours. TECHNODRUG closed at Tk 41.10, up 7.31% on the day, on volume of 4.25 million shares worth Tk 170 million.
Five days earlier, BRAC Bank’s Tk 700 crore subordinated bond listed on the DSE Alternative Trading Board — the first bank bond on the new platform. The infrastructure for corporate debt instruments in Bangladesh has been quietly assembling itself for months. Now a pharma company is walking onto it. That is the story. The question is why pharma, and why now.
The Board Decision and the Market’s Vote
The 196th Board Meeting did not issue a long press release. The DSE notice records the essentials: an EGM to be held, the purpose being the issuance of a bond of BDT 50.00 crore. The bond type referenced is convertible — the kind of instrument that allows debt to morph into equity at a future date on pre-agreed terms.
Convertibility is the part that matters for an equity investor. A straight bond is a balance-sheet event. A convertible bond is a future dilution risk wrapped around a present interest expense. And yet the stock rose 7.31%, climbing from Tk 38.30 to Tk 41.10, with an intraday high of Tk 41.60 — within Tk 0.60 of its 52-week high of Tk 42.20. The market did not punish the announcement. It rewarded it.
That tells you what the market believes the proceeds will fund.
The NPL Crisis That Is Rewiring Corporate Finance
Bangladesh’s banking sector non-performing loan ratio stood at 30.6% as of December 2025, having peaked at 34.6% in June. Default loans hit a 25-year high. The implication for any company that has historically rolled short-term working capital lines through commercial banks is direct: terms are tightening, spreads are widening, and renewal is no longer the formality it was three years ago.
The pharma sector specifically has been a heavy user of bank credit. API manufacturing, export compliance upgrades, and inventory financing all draw on facilities that get repriced at every roll. When 15 of the 36 listed banks landed in the Z category in early May, the message to corporate treasurers was unambiguous. Bank credit is no longer the cheap, deep, dependable funding source it once was.
A convertible bond at the corporate level does several things at once. It locks in a tenor longer than any working-capital facility. It removes the renewal risk. And — because it is convertible — it carries a lower coupon than a straight bond, which keeps the interest expense manageable.
A Corporate Bond Market That Has Finally Found Its Cadence
The names that have moved in the last six weeks are not random. Bank Asia announced a Tk 1,000 crore green sustainable subordinated bond on May 7. BSEC approved City Bank’s Tk 1,200 crore bond in early April. EBL is preparing a Tk 800 crore zero-coupon issue. Pubali Bank has signaled a Tk 500 crore subordinated bond.
Until now, these have all been banks raising regulatory capital. TECHNODRUG is the first non-bank, non-financial issuer of size to walk onto the same platform with a similar instrument, in the same week the ATB began listing bank paper. The Tk 50 crore size is modest compared to the bank deals. It is also exactly the right size for a first-mover from a sector that has never tested institutional bond demand.
For pharma specifically, the precedent matters more than the amount. If TECHNODRUG’s EGM approves the issuance and the bond clears at acceptable terms, the rest of the listed pharma names — and there are several, including the heavyweights — gain a template.
What TECHNODRUG’s Fundamentals Justify
The stock is not cheap on traditional metrics. The unaudited trailing P/E sits at 26.12, the audited at 23.35. Nine-month EPS for FY26 is Tk 1.18, with Q3 EPS of Tk 0.31 — a slight sequential softening from the H1 run-rate of Tk 0.87 across two quarters. NAV per share rose from Tk 27.74 in 2023 to Tk 33.11 in 2024.
Paid-up capital is Tk 132 crore against authorised capital of Tk 200 crore, with reserves and surplus of Tk 271.6 crore. The company has paid 10% cash for 2025 and 12% for 2024 — modest but consistent. The IPO was Tk 100 crore in 2024, which makes a Tk 50 crore bond exactly half the size of the equity raise that brought the company to market.
That ratio is the part to remember. Techno Drugs is not replacing equity with debt — it is adding debt at half the size of its IPO, and signalling that the next leg of capital strategy will not require coming back to equity investors. For a pharma sector that has been heavily reliant on equity rounds, that is the trajectory change worth watching.
The bond market took eight years to find its footing in Bangladesh. The first pharma issuer just walked through the door.